Yokoyama M, Nemoto K, Kanemura M, Kitahara K, Oda H, Murata H, Matsunaga Y
Department of Urology, Toranomon Hospital.
Hinyokika Kiyo. 1998 Nov;44(11):789-94.
Between August 1983 and April 1996, 53 testicular germ cell tumors in 52 patients were treated at Toranomon Hospital. The average age of the patients was 36.1 years (range 21-89). The affected side was the right side in 24, left in 27 and bilateral in 1 case. Of the 53 tumors 34 (64.2%) were seminoma and 19 (35.8%) were non-seminomatous germ cell tumor (NSGCT). High ligation orchiectomy was performed in all cases. Of 29 stage I seminomas, post-operative adjuvant radiotherapy was performed in 6 cases prior to 1991. None of these tumors recurred. Two cases of relapses (8.7%) were found among the 23 stage I seminomas followed by surveillance. Of 8 stage I NSGCTs followed by surveillance, 4 (50.0%) tumors which contained embryonal carcinoma element and vascular invasion relapsed within 12 months after orchiectomy. A case of stage IIA seminoma was treated successfully by irradiation. Seven cases of stage II (3 seminomas and 4 NSGCTs) and 8 cases of stage III (1 seminoma and 7 NSGCTs) as well as cases of 6 stage I patients who developed relapse during surveillance were treated by VAB-6 chemotherapy. Of these 21 cases, 11 (52.4%) achieved complete response (CR) and 10 (47.6%) partial response (PR). Salvage surgery and/or additional chemotherapy was successful to bring the 10 PR cases into CR condition. One NSGCT patient, however, died of electrolyte imbalance during the maintenance chemotherapy for disease progression after achieving CR. All 34 patients with seminomas and 18 of the 19 with NSGCTs were alive without evidence of disease after a mean follow up period of 61.1 months (range 4-150 months).
1983年8月至1996年4月间,虎之门医院收治了52例患者的53例睾丸生殖细胞肿瘤。患者的平均年龄为36.1岁(范围21 - 89岁)。患侧为右侧24例,左侧27例,双侧1例。53例肿瘤中,34例(64.2%)为精原细胞瘤,19例(35.8%)为非精原生殖细胞肿瘤(NSGCT)。所有病例均行高位睾丸切除术。29例I期精原细胞瘤中,1991年前有6例行术后辅助放疗,这些肿瘤均未复发。在23例接受观察的I期精原细胞瘤中,发现2例复发(8.7%)。在8例接受观察的I期NSGCT中,4例(50.0%)含有胚胎癌成分且有血管侵犯的肿瘤在睾丸切除术后12个月内复发。1例IIA期精原细胞瘤经放疗成功治愈。7例II期(3例精原细胞瘤和4例NSGCT)、8例III期(1例精原细胞瘤和7例NSGCT)以及6例在观察期间复发的I期患者接受了VAB - 6化疗。这21例中,11例(52.4%)达到完全缓解(CR),10例(47.6%)部分缓解(PR)。挽救性手术和/或额外化疗成功使10例PR患者达到CR状态。然而,1例NSGCT患者在CR后因疾病进展接受维持化疗期间死于电解质失衡。34例精原细胞瘤患者和19例NSGCT患者中的18例在平均随访61.1个月(范围4 - 150个月)后存活,无疾病证据。